Yang Dehao, Chen Feng, Ren Junli, Wang Lingsheng, Zhu Zhangjing, Wu Zihao, Jin Qiaoqiao, Luo Yuwen, Huang Haoyang, Zhu Baoyi, Zhang Yang, Lin Yuchen, Zhou Linxuan, Mu Guozhu, Chen Guangyong
Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
J Neurol. 2024 Dec 12;272(1):23. doi: 10.1007/s00415-024-12779-2.
Depression and decreased dopamine transporter (DAT) availability are prevalent in Parkinson's disease (PD), yet early predictive biomarkers are lacking. This study investigates the longitudinal associations between cerebrospinal fluid (CSF) neuroglial activation markers, sTREM2 and YKL-40, and depression, as well as DAT availability, in PD patients.
We analyzed data from 172 PD subjects and 80 matched healthy controls from a large longitudinal study. A generalized linear mixed-effects model assessed the longitudinal associations of CSF sTREM2 and YKL-40 with depression and DAT availability. Causal mediation analysis determined if DAT decline mediated the effects of sTREM2 and YKL-40 on depression.
Cross-sectional analysis revealed a negative correlation between CSF sTREM2 and baseline depression scores in PD patients. CSF YKL-40 negatively correlated with baseline left caudate nucleus, left anterior putamen, and right anterior putamen specific binding ratios (SBR). Longitudinally, higher baseline CSF sTREM2 predicted faster depression progression (β = 0.828, p < 0.001) and a rapid decline in right putamen SBR (β = 0.072, p = 0.016). Similarly, higher baseline CSF YKL-40 predicted faster depression progression (β = 0.586, p = 0.004) and a decline in left anterior putamen SBR (β = 0.058, p = 0.035). Causal mediation analysis indicated that baseline CSF sTREM2 accelerated depression progression via its effect on right putamen and right anterior putamen SBR (Indirect effect = 0.103, p = 0.020; Indirect effect = 0.129, p = 0.016).
CSF sTREM2 and YKL-40 are effective predictors for depression and DAT decline in PD, suggesting that neuroglial activation-induced dopaminergic neuron apoptosis significantly contributes to depression onset in PD.
抑郁症和多巴胺转运体(DAT)可用性降低在帕金森病(PD)中很常见,但缺乏早期预测生物标志物。本研究调查了帕金森病患者脑脊液(CSF)神经胶质细胞激活标志物、可溶性触发受体表达分子2(sTREM2)和几丁质酶-3样蛋白1(YKL-40)与抑郁症以及DAT可用性之间的纵向关联。
我们分析了来自一项大型纵向研究的172名帕金森病受试者和80名匹配的健康对照的数据。广义线性混合效应模型评估了脑脊液sTREM2和YKL-40与抑郁症和DAT可用性之间的纵向关联。因果中介分析确定DAT下降是否介导了sTREM2和YKL-40对抑郁症的影响。
横断面分析显示,帕金森病患者脑脊液sTREM2与基线抑郁评分呈负相关。脑脊液YKL-40与基线左侧尾状核、左侧前壳核和右侧前壳核特异性结合率(SBR)呈负相关。纵向来看,较高的基线脑脊液sTREM2预示着抑郁进展更快(β = 0.828,p < 0.001)和右侧壳核SBR快速下降(β = 0.072,p = 0.016)。同样,较高的基线脑脊液YKL-40预示着抑郁进展更快(β = 0.586,p = 0.004)和左侧前壳核SBR下降(β = 0.058,p = 0.035)。因果中介分析表明,基线脑脊液sTREM2通过其对右侧壳核和右侧前壳核SBR的影响加速了抑郁进展(间接效应 = 0.103,p = 0.020;间接效应 = 0.129,p = 0.016)。
脑脊液sTREM2和YKL-40是帕金森病抑郁症和DAT下降的有效预测指标,表明神经胶质细胞激活诱导的多巴胺能神经元凋亡显著促成了帕金森病抑郁症的发病。